ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Additionally, this strategy may also suppress the emergence of BCR-ABL–independent clones, delay and possibly prevent transition ofCML to blast crisis (BC), and yield greater activity in advanced CML and Ph+ ALL [23].